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I. The Wonders of Modern Medicine and the Rise of the 
Pharmaceutical Industry 
Medical advances have altered the landscape of society in western 
nations.  Today, some diseases that were fatal just 70 years ago are now 
either easily curable or completely eradicated.1 Other illnesses that were 
considered incurable just 25 years ago, like AIDS, are now treatable, chronic 
conditions.2  The Western world no longer fears contracting once deadly 
diseases like smallpox or measles.3  Fortunately, many of the dangerous diseases 
of our ancestors are curable with prescription medicine or other forms of 
advanced treatment.  In fact the population of individuals over the age of 85 is 
expected to increase by roughly 350% between 2010 and 2050.4 
Although it is remarkable to consider how far medicine has come, it is 
equally as exciting to consider where medicine is headed.  Some medical 
professionals think that the children of Generation Z will regularly live to be 
about 100 years old thanks in large part to the exponential advancement of 
 
 1.   See Kevin Berman, Smallpox, MEDLINEPLUS, https://medlineplus.gov/ency/article/00 
1356.htm (last updated Apr. 14, 2015), (noting smallpox is essentially eradicated today); see also 
Erin Brodin, Seven Human Diseases the World is on the Cusp of Eradicating, BUSINESS INSIDER 
(May 14, 2015, 11:48 AM), http://www.businessinsider.com/diseases-that-are-almost-eradicated-
2015-5/#measles-1 (listing seven diseases that are close to eradication thanks to modern medicine).  
Specifically, the author notes that measles, rubella, polio, guinea worm, lymphatic filariasis, 
onchocerciasis, and mumps as diseases that are close to being wiped out by medicine. 
 2.  See Living with HIV, CTR. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/ 
actagainstaids/basics/livingwhiv.html (last updated Aug. 24, 2016) (discussing tips and 
responsibilities associated with living with HIV); see also A Timeline of HIV/AIDS, AIDS.GOV, 
https://www.aids.gov/hiv-aids-basics/hiv-aids-101/aids-timeline/ (last visited Mar. 26, 2017). 
 3.  See Smallpox, COMMUNICABLE DISEASE CONTROL & PREVENTION, http://www.sfcdcp.org/ 
smallpox.html (last visited Mar. 26, 2017).  Specifically, it is noted that the last case of smallpox in the 
U.S. was in 1949, and the last case of smallpox in the world was in 1977 in Somalia. 
 4.  See Laura F. Friedman, ‘One of Societies Greatest Achievements’ – In a Simple Chart of 
The Past 175 Years, BUSINESS INSIDER (June 19, 2015, 4:40 PM), http://www.businessinsider. 
com/how-has-life-expectancy-changed-throughout-history-2015-6 (citing the management of 
infectious diseases as a main cause for increased life expectancy). 
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medicine.5  In 2016, a man was successfully given two new arms that are 
expected to become functional.6  Frequently it is reported that a cure for 
cancer is imminent and life expectancies are increasing for almost all forms 
of cancer.7  There is evidence to suggest that a vaccine to treat Ebola is closer 
than most people might expect.8 
Notwithstanding incredible progress, medical advancements continue 
and it is clear more can be done to ease suffering and prolong life.  
Developing, testing and researching new treatments for patient use in the 
United States is an arduous process, and it is both expensive and time 
consuming.9  Every prescription drug that is available to the masses has to 
first pass through the clinical trial process.10 
Generally, a clinical trial in the United States subject to FDA guidelines 
is a four-step phase or process.11  Phase one of a clinical trial consists of 
highly controlled tests with a very small number of people, which is aimed 
at evaluating safety, dosage, and potential side effects.12  Phase two increases 
the number of people in the study, and further assesses safety and 
 
 5.  See Joseph Brownstein, Most Babies Born Today May Live Past 100, ABC NEWS, 
http://abcnews.go.com/Health/WellnessNews/half-todays-babies-expected-live-past-100/story?id 
=8724273 (Oct. 1, 2009) (discussing how children born in 2009 will most likely live to be older 
than 100). 
 6.  See Jacqueline Howard, Double Arm Transplant Will Allow Veteran ‘To Pursue My 
Dreams’, CNN (Oct. 5, 2016 7:44 PM), http://www.cnn.com/2016/10/05/health/double-arm-
transplant-veteran-john-peck. 
 7.  See Anna Magee, How Close Are We To Curing Cancer?, THE TELEGRAPH (Mar. 21, 
2016, 7:00 AM), http://www.telegraph.co.uk/wellbeing/health-advice/how-close-are-we-to-curing 
-cancer/; see also Anna Hodgekiss, Are We Nearing A Cure For Cancer? Holy Grail is Closer 
Than Ever, Oncologist Claims, DAILY MAIL (May 30, 2016 9:38 AM), http://www.dailymail. 
co.uk/health/article-3616249/Are-nearing-cure-cancer-Holy-grail-closer-oncologist-claims.html; 
Greg Jones, Why Are Cancer Rates Increasing?, CANCER RESEARCH CTR (Feb. 4, 2015), 
http://scienceblog.cancerresearchuk.org/2015/02/04/why-are-cancer-rates-increasing/ (noting that 
“more people are beating cancer today than ever before. Survival has doubled in the last 40 years.  
And half of people diagnosed will survive their cancer for more than 10 tears, an all-time high.”). 
 8.  See Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE) Q&A, CTR. FOR 
DISEASE CONTROL & PREVENTION, http://www.cdc.gov/vhf/ebola/strive/qa.html (last updated 
Apr. 20, 2016); see also German Center for Infection Research, Ebola Vaccine: Promising Phase 
I Trials, SCIENCEDAILY (May 3, 2016), https://www.sciencedaily.com/releases/2016/05/1605031 
31401.htm. 
 9.  See Yevgeniy Feyman, Shocking Secrets of FDA Clinical Trials Revealed, FORBES (Jan. 
24, 2014), http://www.forbes.com/sites/theapothecary/2014/01/24/shocking-secrets-of-fda-clinical 
-trials-revealed/#7d5a08f92279. 
 10.  See Clinical Trials, PHRMA, http://www.phrma.org/advocacy/research-development/ 
clinical-trials (last visited Mar. 28, 2017) (discussing the process and steps of the clinical trial process). 
 11.  See Step 3: Clinical Research, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/ForPat 
ients/Approvals/Drugs/ucm405622.htm (last updated Oct. 14, 2016). 
 12.  Id. (noting first step of clinical trial process). 
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effectiveness.13  During phase three, the experimental drug is administered 
to large groups of people, and is aimed at confirming effectiveness through 
monitoring and trial data collection.14  Lastly, phase four occurs after the 
drug is on the market to monitor risks associated with long-term use and the 
drug’s effectiveness in various populations.15 
According to the FDA, 70% of drugs pass phase one, 33% pass phase 
two and 25% to 30% pass phase three.16  To put those numbers into more 
understandable terms, according to the FDA, roughly six out of every one 
hundred drugs that begin the clinical trial process make it past phase three.  
Moreover, some sources suggest that the time from lab to market for a new drug 
is about 15 years,17 and costs can be upwards of $30 to $40 million just for the 
first three phases of a clinical trial, and then another $30 to $40 million if the 
drug makes it to phase four.18  Some studies even suggest that when accounting 
for all the “behind the scenes” costs, the average cost of getting a drug from lab 
to market could be as high as $1.3 billion.19 
These high costs and lengthy processes naturally raise questions — how 
can this process be improved?  Under the construct of the burdensome 
regulations and requirements, how can medicine and the pharmaceutical 
industry meet the needs of patients and future generations faster, safer, and 
more economically?  How can the sponsoring pharmaceutical companies, 
contracted research organizations, site investigators, and others reduce the 
time it takes a treatment or drug to go from lab to market?  One option is to 
expand the use of software platforms to reduce cycle times throughout the 
clinical trial process. 
Commensurate, and even surpassing the profound advancements in 
Western medicine in the last century, software, communication, imaging and 
related technologies have been exponentially advancing in the last several 
 
 13.  Id. (noting second step of clinical trial process). 
 14.  Id. (noting third step of clinical trial process). 
 15.  Id. (noting fourth step of clinical trial process). 
 16.  See id. (stating what percentage of drugs pass through each phase). 
 17.  See Clinical Trials 101, CROHNS & COLITIS FOUND. OF AM., http://www.ccfa.org/resou 
rces/clinical-trials-101 (last visited Mar. 28, 2017) (noting length of average clinical trial). 
 18.  See Aylin Sertkaya et al., Examination of Clinical Trial Costs and Barriers for Drug 
Development, E. RESEARCH GRP. (July 25, 2015), https://aspe.hhs.gov/report/examination-clinic 
al-trial-costs-and-barriers-drug-development. 
 19.  See Avik S. A. Roy, Stifling New Cures: The True Cost of Lengthy Clinical Drug Trials, 
5 PROJECT FDA REPORT, (March 2012) (discussing the behind the scenes costs associated with 
clinical trials, and how those costs can drive the total cost to over $1 billion). 
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decades.20  Technological and medical advancements go hand in hand.21  
Other industries that are of similar size to healthcare and pharmaceuticals 
have evolved their business models to incorporate and accelerate growth and 
success using technological advances.  For example, in the financial services 
industry, virtually all major banks have some form of online banking, and 
according to recent research, about 50% of United States adults use online 
banking.22  Further, about 35% of cell phone users use their smart phones to 
bank online.23  There are even some banks that are exclusively online and 
have no physical, brick and mortar branches.24 
So, with technology permeating so many facets of other industries, why 
has the medical and pharmaceutical industry lagged in matching the pace of 
technological advancement?  Specifically, what are the legal and policy risks 
associated with hastening the clinical trial process by utilizing technology 
based clinical trial platforms versus traditional paper-based methods?  That 
is the question this article seeks to answer. 
First, this article will look to the recent legal trends surrounding 
technology in healthcare and the pharmaceutical industry generally.  Then, 
this article will analyze traditional paper intensive approaches to key 
elements of clinical trials including; site feasibility, document distribution, 
and informed consent and discuss how those areas could be improved by the 
use of technology.  Potential new liability exposures will be analyzed in light 
of the expanded use of technology in the clinical trial process.  The policy 
section will discuss steps regulatory bodies have taken to embrace 
technological advances, and project where technology and medicine are 
headed.  Finally, this article will conclude with a policy discussion that 
compares the benefits of new technologies to possible risk increases and 
suggest ways that the laws and regulations can continue to evolve to harness, 
expand, and encourage new technologies. 
 
 20.  See Max Roser, Technological Progress, OUR WORLD IN DATA (2016), https://ourworld 
indata.org/technological-progress/ (discussing the exponential growth of technology). 
 21.  See Bianca Banova, The Impact of Technology on Healthcare, AM. INST. OF MED. SCI. & 
EDUC. (Mar. 28, 2013), https://www.aimseducation.edu/blog/the-impact-of-technology-on-healthcare. 
 22.  See Susannah Fox, 51% of U.S. Adults Bank Online, PEW RESEARCH CTR. (Aug. 7, 2013), 
http://www.pewinternet.org/2013/08/07/51-of-u-s-adults-bank-online; see also Evan Bakker, 
Technology is Disrupting the Financial Services Industry – Here’s How, BUS. INSIDER (Feb. 22, 
2016), http://www.businessinsider.com/technology-is-changing-the-financial-services-industry-
2016-1. 
 23.  See id. 
 24.  See ALLY FINANCIAL, https://www.ally.com/about/ (noting that Ally is a completely 
online bank); see also Marycela Diaz-Unzalu, Technology Trends Affecting the Banking Industry, 
FED. RESERVE BANK OF ATLANTA (Mar. 28, 2014), https://frbatlanta.org/education/publications/ 
extra-credit/2014/spring/technology-trends-affecting-banking-industry. 
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II. Background: The Intersection of Law, Technology, Medicine, 
and Business 
Since the late 1990s, policy and legislative steps have been taken in the 
United States to promote the implementation and adoption of electronic 
business practices.  In 1999, the National Conference of Commissioners on 
Uniform State Laws (NCCUSL) promulgated the Uniform Electronic 
Transactions Act (UETA).25  According to the NCCUSL, the goal of the 
UETA was to make a “comprehensive effort to prepare state law for the 
electronic commerce era.”26  As of 2016, the UETA has been adopted by 47 
states,27 and governs “electronic records and electronic signatures relating to 
a transaction.”28 
One year later, the federal government joined the e-commerce movement 
by enacting the Electronic Signatures in Global and National Commerce Act 
(hereafter “ESIGN”).29  Effectively, this act assured that electronic signatures 
and agreements would be given the same enforceability as paper agreements.30  
Although neither the ESIGN Act nor the UETA are directly implicated in the 
discussion relevant to this article, they gave electronic agreements and 
signatures the same legal force as paper agreements and signatures.31  Without 
the backbone of these acts, e-commerce and e-business (and thus, e-clinical 
trials) would carry no legal weight at all.32 
 
 25.  See Electronic Transactions Act Summary, NAT’L CONFERENCE OF COMM’RS ON UNIF. 
STATE LAWS, http://www.uniformlaws.org/ActSummary.aspx?title=Electronic%20Transactions 
%20Act (last visited Mar. 28, 2017). 
 26.  See id.  Although every state that has adopted the UETA has codified it in their own way, 
an example of how the UETA was written into law can be seen in FLA. STAT. ANN. § 668.50 
(LexisNexis 2016). 
 27.  See Electronic Transactions Act, NAT’L CONFERENCE OF COMM’RS ON UNIF. STATE 
LAWS, http://www.uniformlaws.org/Act.aspx?title=Electronic%20Transactions%20Act (last 
visited Mar. 28, 2017) (showing map of what states have adopted the UETA). 
 28.  NAT’L CONFERENCE OF COMM’RS ON UNIF. STATE LAWS, supra note 25. 
 29.  See 15 USCS § 7001 (discussing provisions of the ESIGN Act). 
 30.  See 15 USCS § 7001(a)(1) (“a signature, contract, or other record relating to such 
transaction may not be denied legal effect, validity, or enforceability solely because it is in 
electronic form”).  Further, § 7001(a)(2) states “a contract relating to such transaction may not be 
denied legal effect, validity, or enforceability solely because an electronic signature or electronic 
record was used in its formation.” 
 31.  See id. 
 32.  See Howard Burde, The HITECH Act – An Overview, 13 AMA J. OF ETHICS, (VIRTUAL 
MENTOR) no. 3, 2011 at 172–75. 
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A.  The Dynamic Duo of HIPAA and HITECH 
1.  The Health Insurance Portability and Accountability Act 
In 1996, congress passed the Health Insurance Portability and 
Accountability Act (hereinafter “HIPAA”).33  Although HIPAA affected a 
number of areas of the law, it is most known for the impacts it has on patient and 
medical record privacy.34  Specifically, Section 264 of the Administrative 
Simplification provisions is commonly referred to as the “Privacy Rule.”35  The 
main goal of HIPAA and the Privacy Rule specifically is to “define and limit the 
circumstances in which an individual’s protected health information may be 
used or disclosed by covered entities.”36 
HIPAA’s Privacy Rule “[applies] to health plans, health care 
clearinghouses, and to any health care provider who transmits health 
information in electronic form.”37  The Privacy Rule is focused on 
minimizing the release of individually identifiable health information (IIHI) 
by any of the abovementioned-covered entities.38  In addition to obvious 
examples of IIHI, things like credit card numbers and telephone numbers are 
also considered to be sources of IIHI.39  Further, the Privacy Rule enacted a 
“minimum necessary” standard for disclosing medical information, which 
requires that covered entities make “reasonable efforts to limit protected 
health information to the minimum necessary to accomplish the intended 
purpose of the use, disclosure, or request.”40  In the early 2000s, the Office 
for Civil Rights (the branch of the Department of Health and Human Services 
responsible for investigating HIPAA violation claims) was regularly 
receiving “over one hundred privacy-related complaints per week.”41 
In addition to the privacy components of HIPAA, the law also includes 
security measures.  The purpose of the security rule is to require “appropriate 
administrative, physical and technical safeguards to ensure the 
 
 33.  See Summary of the HIPAA Privacy Rule, U.S. DEP’T OF HEALTH & HUMAN SERV., 
https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations/ (last visited Mar. 28, 
2017), (giving an overview of HIPAA). 
 34.  See The HIPAA Privacy Rule, U.S. DEP’T OF HEALTH & HUMAN SERV., https:// 
www.hhs.gov/hipaa/for-professionals/privacy/ (last visited Mar. 28, 2017). 
 35.  See U.S. DEP’T OF HEALTH & HUMAN SERV., supra note 33. 
 36.  See Elizabeth Hutton & Devin Barry, 2004 Privacy Year In Review Annual Update: Medical: 
Privacy Year In Review: Developments in HIPAA, 1 INFO. SOC’Y J.L. & POL’Y 347, 352 (2005). 
 37.  See U.S. DEP’T OF HEALTH & HUMAN SERV., supra note 33 (discussing the HIPAA 
privacy rule). 
 38.  See Hutton & Barry, supra note 36, at 352. 
 39.  Id. 
 40.  See 45 C.F.R. § 164.502(b)(1). 
 41.  See Hutton & Barry, supra note 36, at 355. 
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confidentiality, integrity, and security of electronic protected health 
information.”42  In today’s world, the very real threat of computer hacking 
by third parties is a serious consideration for the healthcare industry, being 
hacked and the resulting exposure of IIHI would open up a covered entity to 
liability under HIPPA.43 
2.  The Health Information Technology for Economic and Clinical Health Act 
In 2009, HIPAA, and technology in health and medicine took a further 
leap into the technology era with the enactment of the Health Information 
Technology for Economic and Clinical Health Act (HITECH Act).44  The 
HITECH Act was passed as part of the American Recovery and 
Reinvestment Act, which was President Obama’s stimulus package aimed at 
pulling the country out of a significant and prolonged recession following 
the collapse of financial markets due to poor mortgage loan practices and 
securitization.45  The goal of the HITECH Act was to implement a national 
system of electronic record keeping for medical records.46  The HITECH Act 
aimed to accomplish widespread adoption of Electronic Health Record 
Systems (EHRs) with the use of incentive payments to health care industry 
clinicians and participants.47 
Although the HITECH Act is predominantly aimed at the 
implementation of EHR systems across the United States, it also facilitates 
the enforcement of HIPAA.48  In addition to expanding the definition of who 
must comply with HIPAA, the HITECH Act also created a security breach 
notification requirement.49  In the event of a breach, the company responsible 
for holding the data must notify the affected customers and the government, 
 
 42.  See The Security Rule, U.S. DEP’T OF HEALTH & HUMAN SERV., http://www.hhs. 
gov/hipaa/for-professionals/security/ (last visited Mar. 28, 2017). 
 43.  See Leon Rodriguez, Privacy, Security, and Electronic Health Records, HEALTH IT BUZZ 
(Dec. 12, 2011), https://www.healthit.gov/buzz-blog/privacy-and-security-of-ehrs/privacy-security 
-electronic-health-records/; see also Kevin McCarthy, HIPAA and Hacking: What You Need to 
Know, NUEMD (Apr. 14, 2016), http://www.nuemd.com/news/2016/04/14/hipaa-hacking-you-
need-know (noting the increase in hacking attempts aimed at healthcare infrastructure). 
 44.  See Kirk J. Nahra, A New HIPAA Era Emerges, 1005 PLI/PAT 467, 471 (2010) (Westlaw). 
 45.  See About the Recovery Act, WHITE HOUSE, https://www.whitehouse.gov/recovery/ 
about (last visited April 19, 2017). 
 46.  See Kara J. Johnson, HITECH 101, AM. BAR ASS’N, http://www.americanbar.org/grou 
ps/young_lawyers/publications/the_101_201_practice_series/hitech_101.html (last visited Mar. 
28, 2017). 
 47.  See id. (positing that the HITECH Act “was passed as a monetary incentive plan for 
hospitals to begin converting to electronic records.”). 
 48.  See id. (reasoning that “HITECH significantly changes both enforcement and sanctions 
with regard to health care privacy and security requirements under HIPAA.”). 
 49.  See Nahra, supra note 44. 
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and if the breach affects more than 500 people, the media must also be 
notified.50  By requiring notification to affected parties, the HITECH Act not 
only holds record holders more accountable but also aims to increase and 
preserve the trust between patients and entities holding their health 
information in electronic format.51 
Prior to the implementation of HITECH, third-party service providers 
were not directly subject to liability for violations of HIPAA; instead they 
could be held liable privately to the covered entity utilizing their services 
under a breach of contract claim.52  However, pursuant to HITECH, 
“business associates are now directly subject to civil and criminal penalties 
under HIPAA if they violate . . . security safeguard requirements or the terms 
of their business associate agreements.”53  Thus, HITECH increased the 
scope of HIPAA by allowing business associates to be held directly liable 
for violations of the privacy rule.54 
Additionally, HITECH dramatically increased the possibility of 
enforcement of HIPAA because it allows a state attorneys general to bring 
HIPPA enforcement actions, in addition to ramping up the penalties violators 
can face.55  Prior to the HITECH Act, HIPAA violators were subjected to 
penalties of $100 per known violation, with a damages cap of $25,000 per 
year.56  Considering that the size of the United States healthcare industry 
where many large players have revenues in the tens of billions or more,57 
with a total market size of upwards of $3 trillion, the $25,000 fine levels may 
have been inadequate to act as a deterrent.58  The stakes are higher under the 
 
 50.  See HITECH Breach Notification Rule, U.S. DEPARTMENT OF HEALTH AND HUMAN 
SERVICES, https://www.hhs.gov/hipaa/for-professionals/breach-notification/ (last visited Mar. 28, 
2017) (analyzing the breach notification requirement implemented by the HITECH Act). 
 51.  See id. 
 52.  See Norbert F. Kugele, HIPPA Goes HITECH: How the HITECH Amendments to HIPPA 
Impact Employer-sponsored Health Plans, 35 MI TAX L. 19, 20 (2009). 
 53.  See id. 
 54.  See id. 
 55.  Health Information Technology for Economic and Clinical Health Act, § 13410, 
amending Social Security Act § 1176, codified at 42 U.S.C. § 1320d-5; see also Health Information 
Technology for Economic and Clinical Health Act, § 13410(e)(1); see also HIPAA Violations and 
Enforcement, AM. MED. ASS’N, http://www.ama-assn.org/ama/pub/physician-resources/solutions-
managing-your-practice/coding-billing-insurance/hipaahealth-insurance-portability-accountability 
-act/hipaa-violations-enforcement.page? (last visited Mar. 28, 2017). 
 56.  See Kugele, supra note 52, at 19-20. 
 57.  See Laura Lorenzetti, The 10 Biggest Health-Care Companies in the Fortune 500, 
FORTUNE (June 20, 2015), http://fortune.com/2015/06/20/fortune-500-biggest-healthcare-compan 
ies/ (noting several healthcare companies listed in the Fortune 500 with annual revenues between 
$50 to $140 billion). 
 58.  See Dan Munro, U.S. Healthcare Hits $3 Trillion, FORBES (Jan. 19, 2012, 11:52 PM), 
http://www.forbes.com/sites/danmunro/2012/01/19/u-s-healthcare-hits-3-trillion/#66b0f34c2f67. 
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HITECH Act, with penalties for HIPAA violations ranging from $100 per 
violation to $50,000 per violation, with an annual cap of $1.5 million in 
penalties.59 
a.  The Impact of HIPAA and HITECH on the Clinical Trial Ecosystem 
Although HIPAA and HITECH are Acts aimed at the implementation, 
security, and privacy of EHRs, they both have substantial impacts 
throughout the entire healthcare system.  Recently, the impact of these laws 
has become even more pronounced as the clinical trial process is, albeit 
slowly, going digital.60  The shift from paper to digital clinical trials provides 
the framework for speeding up the time from lab to market and will also save 
companies who sponsor clinical trials large sums of money.  Some research 
suggests that life science and other pharmaceutical companies could save as 
much as 25% of their annual operating expenditures by working with a 
clinical IT system.61  Thus, it comes as no surprise to discover that 66% of 
the top 50 pharmaceutical companies are currently digitizing certain parts of 
their clinical trial process.62 
Throughout the clinical trial process, IIHI is exchanged between 
companies, clinicians, and patients.  As a result, successfully navigating the 
clinical trial process requires compliance with a number of federal laws, like 
HIPAA and HITECH.  Although there are serious financial and humanitarian 
incentives to digitizing the clinical trial process, pharmaceutical companies are 
hesitant to fully embrace digital clinical trials because of the potential 
compliance issues and the possible increase in liability exposure.63 
 
 59.  See Kugele, supra text accompanying note 52. 
 60.  See eClinical Solutions Market to Surpass $13 Billion by 2024, Dɪɢɪᴛᴀʟ Jᴏᴜʀɴᴀʟ (Oct. 
24, 2016), http://www.digitaljournal.com/pr/3115602. 
 61.  See Elly Earls, Ahead In The Cloud – A New home For Clinical Trial Data, 
Pʜᴀʀᴍᴀᴄᴇᴜᴛɪᴄᴀʟ-Tᴇᴄʜ. (Jan. 31, 2012), http://www.pharmaceutical-technology.com/features/feat 
ureahead-in-the-cloud-a-new-home-for-clinical-trial-data/ (stating “IBM’s research suggests that 
many life sciences organizations could save as much as 25% of their annual operating expenditure 
on clinical IT systems by using cloud computing). 
 62.  See Glenn Keet & Eric Morrie, Top eClinical Trends in 2016, CLINCAPTURE, ᴇCʟɪɴɪᴄᴀʟ 
Tʀᴇɴᴅ (Mar. 9, 2016), http://www.clincapture.com/blog/top-eclinical-trends-in-2016-12-2/.  The 
statistics from this article are specific to eConsent adoption, not total eClinical trial adoption.  
However, eConsent adoption is one of the biggest hurdles many companies need to overcome in 
order to entirely digitize their clinical trial process.  See also Electronic Consent Management: 
Landscape Assessment, Challenges, and Technology, Hᴇᴀʟᴛʜʜɪᴛ.ɢᴏᴠ (Oct. 29, 2014), available at 
https://www.healthit.gov/sites/default/files/privacy-security/ecm_finalreport_forrelease62415.pdf. 
 63.  For a discussion pertaining to potentially increased liability by digitizing the clinical trial 
process, see infra, notes 86–99, 108–122, and 135–149. 
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b.  A Primer on the Terminology and Business of Clinical Trials 
As was discussed at length in Section I of this article, clinical trials are 
one of the driving forces behind the advancement of medicine.64  Thus, a 
number of entities from the medical industry are involved in some form or 
another.65  For example, a clinical trial is led by a principal investigator who 
is usually a medical doctor.66  Further, the principal investigator is supported 
and assisted by a research team, usually consisting of nurses, other doctors, 
social workers, and health care professionals.67 
Clinical trials are often paid for (or sponsored) by pharmaceutical 
companies or university medical centers.68  However, some federal agencies will 
fund clinical trials for specific diseases that are widespread.  For example, 
federal agencies fund a large proportion of cancer related clinical trials.69 
When a sponsoring party wants to begin work on a clinical trial, they 
can either perform the research and work themselves, or they can recruit a 
contract research Organization or CRO.70  A CRO is a company that is 
recruited and contracted by the sponsor “to manage and lead the company’s 
trials, duties, and functions.”71  A CRO acts as an agent for the sponsor, 
providing expertise and experience in the clinical trial process, while the 
sponsor does not need to hire permanent staff for the position.72  CRO’s can 
fill many roles throughout the clinical trial process, with some CROs 
handling a specific part of the clinical trial and others managing the trial from 
 
 64.  See supra text accompanying notes 16–24. 
 65.  See Learn About Clinical Studies, U.S. NAT’L INST. OF HEALTH, https://clinicaltrials. 
gov/ct2/about-studies/learn (last updated Jan. 2017). 
 66.  See Jeff Kingsley, What is a PI?, ACRP, https://www.acrpnet.org/professional-
development/certifications/pi-certification/ (last visited Mar. 28, 2017) (stating that a “[principal 
investigator] holds a doctoral-level degree (PhD, PharmD, DNP, DO, MD, DDS or equivalent 
degree) and serves as the principal, sub- or co-investigator[.]”) 
 67.  See Responsibilities of the Research Team, OHIO STATE UNIV. CTR FOR CLINICAL & 
TRANSLATIONAL SCI., https://ccts.osu.edu/education-and-training-programs/research-education-a 
nd-training-programs/clinical-research-coordinator-resources/responsibilities-of-the-research-team/ 
(last visited Mar. 28, 2017) (noting that “the research coordinator/nurse oversees and coordinates 
the daily activities of clinical research studies”). 
 68.  See id.; see also Freemantle, N. and Stockten, D., The Commercialization of Clinical 
Research: Who Pays the Piper, Calls the Tune?, OXFORD JOURNALS (Aug. 1, 2004), 
http://fampra.oxfordjournals.org/content/21/4/335.full 
 69.  See Who Conducts Clinical Trials and Who Pays for Them?, BREASTCANCER.ORG, 
http://www.breastcancer.org/treatment/clinical_trials/conduct_pay (last updated Aug. 10, 2016) 
(noting that many cancer related clinical trials are funded by United States Federal Agencies). 
 70.  See Kathlyn Stone, Contract Research Organization, THE BALANCE (May 2, 2016), 
https://www.thebalance.com/contract-research-organizations-cro-2663066. 
 71.  See id. 
 72.  See id. 
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site selection to FDA approval.73  As a result, CROs are becoming 
increasingly popular in the clinical trial world, and can be involved at every 
stage of the research and development process in a clinical trial.74 
3.  What Steps of the Clinical Trial Process Can be Digitized? 
As mentioned in the introduction, the clinical trial process is rather 
lengthy, consisting of a number of steps over several years.75  Addressing the 
impact of digitizing every single step of the clinical trial process is beyond 
the scope of this article, which will focus on a discussion of three separate 
steps in the process that are digitizable and examine the impact of digitizing 
these three specific steps in terms of benefits to patients and the process 
generally, and the effect on possible liability exposure.  The specific 
processes that will be discussed are the site selection process, document 
distribution, and informed consent. 
a.  Site Selection 
When conducting a clinical trial, one of the preliminary steps is finding 
an appropriate site to recruit, interact with and monitor patients participating 
in the trial.  Locating a site consists of finding the right demographics, 
patients, clinicians, hospitals, facilities etc. and can be one of the most 
arduous aspects of the clinical trials process.76  However, the current model 
for site feasibility planning is outdated, and relies on a “crowdsourcing 
approach” instead of data and analytics.77 
Generally speaking, site feasibility “is a process of evaluating the 
possibility of conducting a particular clinical program/trial in a particular 
geographic region with the overall objective of optimum project completion 
 
 73.  See id. 
 74.  See Ed Silverman, Why Contract Research Organizations Are So Hot, Fᴏʀʙᴇs (Oct. 4, 
2011), http://www.forbes.com/sites/edsilverman/2011/10/04/why-contract-research-organizations 
-are-so-hot/#5da56611694b. 
 75.  See supra text accompanying notes 11–17. 
 76.  See Melissa Fassbender, ‘Paradigm Shift Needed’ in Trial Site Selection Process, 
OUTSOURCING-PHARMA (Mar. 31, 2016), http://www.outsourcing-pharma.com/Commercial-
Services/Paradigm-shift-needed-in-trial-site-selection-process (reasoning that “site selection has 
traditionally been performed using manual, and error prone processes, which use historical, siloed 
data — ultimately resulting in too many non-enrolling and under-enrolling sites being selected.”) 
 77.  See Ed Miseta, Proper Feasibility Planning is Critical for Clinical Trial Success, 
CLINICAL LEADER (June 22, 2015), http://www.clinicalleader.com/doc/proper-feasibility-plan 
ning-is-critical-for-clinical-trial-success-0001 (suggesting that data driven site feasibility processes 
will lead to better results); see also Kenneth A. Getz, Is Investigative Site Feasibility Feasible?, 
APPLIED CLINICAL TRIALS ONLINE (July 1, 2008), http://www.appliedclinicaltrialsonline. 
com/investigative-site-feasibility-feasible (noting that “[s]ponsors, CROs and investigative sites 
widely agree that site feasibility assessments are frequently exercises in futility.”) 
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in terms of timelines, targets, and costs.”78  This is usually accomplished by 
sending out feasibility surveys to potential sites, which ask about 
demographics and enrollment prospects.79  However, the surveying method 
can be problematic, because surveys are subject to over and under 
estimations.80  Further, it is not unheard of for potential sites to be 
purposefully overconfident in their enrollment projections in order to win the 
study grant and become a host site for the trial.81 
Therefore, the current process of finding an adequate site to host a 
clinical trial is in many respects left up to chance.82  Depending on the 
complexity of the drug and associated illness that is the subject of a 
prospective clinical trial, finding an adequate site may be very difficult.  As 
an extreme example, any sort of large-scale research pertaining to the Ebola 
outbreak would necessarily have to occur in West Africa, as that is where the 
outbreak of the disease has occurred.83  Locating a site that has the 
technological capabilities to host a clinical trial in West Africa could 
presumably prove difficult. 
Further, even if a site is found, and patients are recruited, it is reported 
that “less than half of studies completed enrollment within the planned 
timeline.”84 Patient recruitment and retention has always been one of the 
biggest hurdles that sponsors and CROs need to overcome.85  Thus, sponsors 
and CROs can be forced to restart the site evaluation process, with less time 
and money than was available at the commencement of the trial.  Regardless 
of the problems that a sponsor could encounter while seeking a site for a 
 
 78.  See Viraj Rajadhyaksha, Conducting Feasibilities in Clinical Trials: An Investment to 
Ensure a Good Study, NAT’L CTR FOR BIOLOGY INFO. (July-Sept. 2010), https://www.ncbi.nlm. 
nih.gov/pmc/articles/PMC3146075/ (discussing the importance of a properly performed site 
feasibility process). 
 79.  See Miseta, supra note 77. 
 80.  See Getz, supra note 77. 
 81.  See id. 
 82.  See Miseta, supra note 77 (noting that “there would also be questions around how the 
sites produced their answers, and whether there was any scientific evidence to back it up.”) 
 83.  See 2014 – 2016 Ebola Outbreak in West Africa, CTR FOR DISEASE CONTROL, 
https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/ (last updated June 22, 2016) (reasoning 
that “since march 2014, West Africa has experienced the largest outbreak of Ebola in history”). 
 84.  See Kenneth A. Getz, Enrollment Performance: Weighing the “Facts”, APPLIED 
CLINICAL TRIALS, (May 1, 2012), http://www.appliedclinicaltrialsonline.com/enrollment-perform 
ance-weighing-facts?id=&sk=&date=&pageID=2; see also Interview by Elisabeth Fischer 
interviewing Marta Rayo Lunar, Trial and Error: Site Selection for Clinical Studies, 
PHARMACEUTICAL-TECH., http://www.pharmaceutical-technology.com/features/feature130340/. 
 85.  See Olivia Diamond, Overcoming Patient Recruitment and Retention Hurdles, MEDRIO 
(Nov. 23, 2015), http://medrio.com/partners/overcoming-patient-recruitment-and-retention-hurdles/ 
(reasoning that “Phase I through Phase III trials are, on average, 30% longer than planned due to 
patient recruitment issues and low patient retention”). 
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clinical trial, the current process is undoubtedly a driving force in the 
exploding time and cost associated with drug development. 
i.  Site Selection and the Impact of Technology 
Utilizing a digital site selection program could likely save a huge 
amount of time and money.  The utilization of a digital database for site 
selection is well within the limits of technology and the law and is already 
being used in the industry.86  Specifically, a central database can store 
information gathered from prior trials and site-reported experience and 
competencies.  This data can include information about investigators, 
patients, disease, or conditions and the success rates of sites that hosted trials 
in the past.  With this wealth of information, computer generated algorithms 
compute and predict which sites would most likely have the optimum results 
for a specific clinical trial.87 
This process would save time and money for both the sponsor and the 
site.  Traditionally, every time a site is considered to host a clinical trial, the 
site must fill out and complete a feasibility survey.88  However, in a digital 
process, a survey would only need to be completed one time, and the answers 
could be stored in a database.  Even Better, potential sites could have access 
to an online application or profile that they can continually update as the 
site’s specific information changes.89 
Utilizing a digital process for site feasibility reduces not only time, but 
also costs associated with printing and mailing surveys required for site 
selection.  Employing a traditional, paper based method, the CRO would 
send potential sites a survey, wait several days for the site to send it back, 
and then transform the answers into useful data.90  However, if a digital 
process was utilized, potential sites could answer a survey one time, and then 
an algorithm would compute the data and suggest the sites that are most 
likely to be successful for each specific clinical trial.91 
 
 86.  See Craig Morgan, It’s Site Selection, Not a Toss of the Dice, CLINICAL INFORMATICS 
NEWS (June 28, 2016), http://www.clinicalinformaticsnews.com/2016/6/27/its-site-selection-not-
toss-dice.aspx. 
 87.  See id. 
 88.  See Ed Miseta, Bring Down The Cost Of Clinical Trials With Improved Site Selection, 
CLINICAL LEADER (Dec. 19, 2013), http://www.clinicalleader.com/doc/bring-down-the-cost-of-
clinical-trials-with-improved-site-selection-0001. 
 89.  See id. 
 90.  See Morgan, supra note 86. 
 91.  See Miseta, supra note 88. 
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A digital site selection process would result in more accurate data.92  If 
a site is asked to fill out a selection survey once, without the potential reward 
of a specific clinical trial, the site is more likely to be candid in their 
responses.93  An approach like this could dissuade a site from responding to 
selection surveys with an eye toward participating in a specific clinical trial, 
because inflating numbers in the hopes of getting one trial may be 
detrimental to getting a better trial in the future.94  By utilizing a fully 
technology based method of site selection, potential sites would only respond 
to one survey, and would be unable to tailor their responses to a specific 
clinical trial.95  Thus, responses could be more reliable, and thus provide 
sponsors and CROs with more accurate data, which would hopefully 
minimize the inclusion of sites that under recruit or are not successful in 
recruiting any participants.96 
Further, neither HIPAA nor HITECH would act as a barrier to the industry 
adopting a digital site selection process.  The data needed to create a site 
selection database would not implicate individually identifiable health 
information; only specific data points are required.  Thus, because the data 
would not be tied to specific people, and all identifying information could be 
stripped away, HIPAA’s privacy rule would not be implicated.97 
The logical endpoint of this approach could be a ranking of different 
sites based on patient recruitment outcomes and success in past clinical trials.  
However, ranking of sites would necessarily be based only on past 
performances, and thus would only include the specific trials that the sites 
had previously hosted.  Accordingly, some site representatives agree that this 
technology would be beneficial to sites too, because it can help determine 
“which data should be viewed as reliable in predicting future behavior, 
 
 92.  See Morgan, supra note 86 (noting that electronic site selection methods can provide 
sponsors “with intelligence based on data documenting sites’ past performance, size of patient 
database, staff expertise in certain therapeutic areas, and ability to produce quality data and manage 
a clinical trial”). 
 93.  See Miseta, supra note 88. 
 94.  See id. 
 95.  See Miseta, supra note 88. 
 96.  For a discussion of problems with the current survey method of identifying sites for 
clinical trials, see supra notes 76-85.  For a discussion specific to fabrication of survey answers and 
how technology can improve the process of site selection, see Sameer Tandon, The State of 
Feasibility Assessments and Strategies to Improve Your Methodology, PHARM. OUTSOURCING 
(Jan. 29, 2014), http://www.clinicaltrialsarena.com/news/operations/the-state-of-feasibility-assess 
ments-and-strategies-to-improve-your-methodology-4986833 (noting that “[s]ites frequently tell 
sponsors what they want to hear and this is often in response to the types of questions being asked.”). 
 97.  For a discussion of HIPAA’s privacy rule, and how it is implicated by Individually 
Identifiable Health Information (IIHI), see supra text accompanying notes 37–41. 
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versus which merely reflects the specifics of a particular study.”98  
Accordingly, a site selection database that is established with collaboration 
by the sites would include only accurate data, and thus would be beneficial 
to both sponsors and sites.99 
b.  Document Distribution 
Due to the large number of people and entities working together on a 
clinical trial, communication and information sharing is a critical part of a 
successful clinical trial.  For example, the efficacy of the trial relies on proper 
distribution of trial related — clinical information.100  Further, credentials and 
training materials must be shared among the healthcare professionals and 
pharmaceutical entities taking part in the trial.101 
In small scale, localized, clinical trials, document distribution is not 
impossibly daunting — most paperwork can be exchanged via trackable 
delivery methods such as certified mail.  However, increasingly in the modern 
era numerous clinical trials are big, multisite, global projects.102  These large, 
multi-site trials are placing new strains on the paper based document distribution 
framework that some industry participants continue to use.103  Further, this 
problem is unlikely to go away, as clinical trials are steadily growing in size, 
geographic disbursement, and therefore complexity.104 
 
 98.  See Morgan, supra note 86. 
 99.  See id. 
 100.  See Vito Anthony Losito, Manage Trial Master Files via Investigative Portals, APPLIED 
CLINICAL TRIALS ONLINE (Feb. 1, 2011), http://www.appliedclinicaltrialsonline.com/manage-
trial-master-files-investigative-portals. 
 101.  See Nick Paul Taylor, Digital Documents: Can Electronic Tools Ease Biopharma’s 
Clinical Trial File Headaches?, FIERCE BIOTECH (Jan. 27, 2014 6:57 AM), http://www. 
fiercebiotech.com/r-d/digital-documents-can-electronic-tools-ease-biopharma-s-clinical-trial-file 
headaches (noting that “sponsors have formed deep collaborations with service providers” and that 
“sharing paper documents in an outsourced system is a headache for sponsors, and the problem is 
magnified by the globalization of late-phase trials”). 
 102.  See Global Clinical Research Market to Reach $60 Billion in 2020, CLINCAPTURE (Nov. 
2, 2015), http://www.clincapture.com/blog/global-clinical-research-market-to-reach-60-billion-in-
2020/ (discussing the expected growth of global clinical trials). 
 103.  See Wenle Zhao et al., An Electronic Regulatory Document Management System for a 
Clinical Trial Network, NAT’L CTR FOR BIOTECHNOLOGY INFO. (Jan. 1, 2011), https://www. 
ncbi.nlm.nih.gov/pmc/articles/PMC2829838/ (reasoning that global clinical trials create new 
challenges for document distribution including “the large number of documents to be collected and 
maintained, the complexity associated with simultaneous multiple project operations, [and] the 
need for document file sharing by multiple owners”). 
 104.  See Taylor, supra note 101; see also Global Trends in Clinical Trial Logistics: 2020 
Perspective, COREX, http://corex-depot.com/expertise/white-papers/global-trends-in-clinical-
trial-logistics-2020-perspective/ (last visited Mar. 15, 2017) (discussing the growth of clinical trials 
on a global scale). 
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Throughout the clinical trial process, the most important documents and 
information available to parties in the trial is commonly referred to as the 
Trial Master File (“TMF”).105  The distribution of the TMF is crucial to the 
safety of participants, along with gathering and maintaining critical FDA 
reportable data throughout the process.  Although TMF distribution seems 
to be a perfect candidate for a transition to electronic distribution, many of 
the industry leaders in the pharmaceutical arena are hesitant to vacate ink 
signature forms.106  However, due to the expected growth of clinical trials, 
and the trend towards utilizing sites around the world, the traditional paper 
method of TMF distribution will need to make serious advances in 
methodology and logistics, or be replaced altogether.107 
i.  Document Distribution and the Impact of Technology 
The process of document distribution is in serious need of a digital 
overhaul.  Digitizing the document distribution process would save both time 
and money, and would likely open communication channels between all the 
parties working on a clinical trial.  Instead of sending documents in the mail, 
instant access is possible in at least two separate ways. 
First, the TMF and other important documents can be securely stored 
on a specific server, which could be accessed remotely.108  By doing 
document distribution by remote access, companies minimize the risk of the 
documents being improperly stored by third parties, lost in transit, or 
intercepted during transport.109  Frankly, document distribution would be 
considered an antiquated term, because the documents are not actually being 
 
 105.  See Losito, supra note 100. 
 106.  See Cutting Edge Information, By 2020, Global Distribution of Electronic TMF 
Documents is Projected to Increase 63% Over 2015, MARKET WIRED (June 8, 2016), 
http://www.marketwired.com/press-release/by-2020-global-distribution-electronic-tmf-document 
s-is-projected-increase-63-over-2015-2132475.htm  (discussing that some companies “believed 
signatures shouldn’t be done electronically for their TMF”). 
 107.  See Sheila Mahoney and Toni Lakin, Moving From Paper to Electronic TMFs, 
CONTRACT PHARMA (Oct. 9, 2013), http://www.contractpharma.com/issues/1013/view_features/ 
moving-from-paper-to-electronic-tmfs (noting that when Paper TMFs are “locked away in a file room, 
other team members need to travel to access it or make special requests for copies to be made”). 
 108.  For an overview and additional background information about remote server access, see 
A Beginner’s Guide to Remote Access Software, REMOTE ACCESS, http://www.remoteaccess.org/ 
(last visited Mar. 15, 2017) (positing that “[c]omputing power and network bandwidth have made 
accessing and sharing data between a variety of different machines across vast distances not only 
easier but also more secure”). 
 109.  See Kevin Jackson, The Top 5 Benefits of Remote Network Monitoring, HELPSYSTEMS 
(Dec. 14, 2016) https://www.helpsystems.com/resources/articles/top-5-benefits-remote-network-
monitoring (noting the security benefits of remote access technology when end to end encryption 
is utilized). 
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distributed, the login credentials are.110  Instead of sending out copies of the 
TMF and other documents, one copy of the documents would be saved to a 
secure server.  Then, the company holding the TMF could manage and 
circulate login credentials.  That way, only one copy of the TMF actually 
exists, but that one copy can be viewed by multiple people simultaneously 
from around the world.111 
Further, the pharmaceutical industry’s reluctance to adopt electronic 
signatures is shortsighted.112  Within the TMF, various forms and releases 
need to be signed by patients and doctors.113  Since the passage of the ESIGN 
Act in 2000, electronic signatures hold the same merit as their ink 
counterparts.114  Additionally, the ESIGN Act bars state law from preempting 
the validity of electronic signatures.115  Although a state may enact their own 
law in place of the ESIGN Act, the state statute must “[specify] the alternative 
procedures or requirements for the use or acceptance (or both) of electronic 
records or electronic signatures to establish the legal effect, validity, or 
enforceability of contracts or other records.”116 
Beyond the ambit of the ESIGN Act, electronic signatures are also 
federally regulated.117  These regulations set out separate validation 
requirements for closed network and open network systems.118  Essentially, 
the regulations outline higher standards and requirements of authentication 
 
 110.  See id. 
 111.  See Jennifer Goldsmith, Shredding Paper, Saving Cash: Going Digital with a Cloud-
Based eTMF, CLINICAL INFORMATICS NEWS (Oct. 30, 2014), http://www.clinicalinformaticsnews 
.com/2014/10/30/shredding-paper-saving-cash-going-digital-cloud-based-etmf.html (reasoning 
“cloud-based eTMFs are easily and securely accessible by all parties”)  (The author also notes that 
an additional benefit of cloud-based TMF systems is that it allows the sponsor to continually update 
the TMF and review the TMF to make sure that it stays in compliance with federal and state laws.).  
Id. 
 112.  See supra text accompanying notes 100-106.  For references to the pharmaceutical industries 
reluctance to adopt electronic signatures for TMFs, see supra text accompanying note 106. 
 113.  See Losito, supra note 100. (stating that “a TMF consists of thousands of pages, and 
includes everything from regulatory documents, correspondence, and data to documentation that 
supports compliance with local regulations”). 
 114.  See 15 U.S.C. § 7001(a)(1) (2000) (stating that “a signature, contract, or other record 
relating to such transaction may not be denied legal effect, validity, or enforceability solely because 
it is in electronic form”). 
 115.  See 15 USCS § 7002 (2000). 
 116.  See 15 USCS § 7002 (a)(2) (2000). 
 117.  See 21 C.F.R. § 11.100 (2017). 
 118.  See 21 C.F.R. § 11.10 (2017) for a list of the controls utilized for closed network systems; 
see also 21 C.F.R §11.30 (2017) for a list of the controls utilized for open network systems.  The 
only difference between the two lists of controls is that the open network systems require all of the 
protections of the closed system plus “additional measures such as document encryption and use of 
appropriate digital signature standards to ensure, as necessary under the circumstances, record 
authenticity, integrity, and confidentiality. 
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and security for any electronic signatures relating to the Food and Drug 
Administration and the Department of Health and Human Services.119  
However, the regulations clearly state that “persons may use electronic 
records in lieu of paper records or electronic signatures in lieu of traditional 
signatures” so long as the requirements of the regulations are met.120  Thus, 
electronic signatures and records are accepted as valid by multiple sources 
of authority from the federal government, and there is no requirement for 
pharmaceutical companies to continue to utilize paper-based methods. 
Another valid concern with electronic document distribution and 
storage is the possibility of being the victim of a cyber-attack, or what is 
more colloquially referred to as hacking.  According to the Department of 
Health and Human Services, since 2010, there have been 240 HIPAA 
violations resulting from hacking that have affected 500 or more people.121  
Although that seems like a high number, when compared to the 764 
incidences of paper, laptop, and desktop computer theft resulting in HIPAA 
violations during the same time frame,122 the risk of being hacked is lower.  
Additionally, by using proper security software, encryption and protocols, 
the risk of being hacked can be substantially reduced.  Most sophisticated 
businesses employ appropriate avoidance tactics such as continually 
updating passwords, utilizing malware-scanning software, and keeping 
software up to date which drastically minimizes the risk of being hacked.123  
So long as affirmative steps are taken to minimize the threat of cyber-attacks, 
electronic document distribution is an excellent way to minimize costs and 
save time throughout the clinical trial process. 
c.  Informed Consent 
The most important part of the clinical trial process from a subject 
protection and ethical viewpoint is obtaining informed consent from the 
individuals who are participating in the clinical trial.  Since the horrors of 
medical experiments during the Nazi era, and the subsequent adoption of the 
Nuremburg Code, informed consent has been the touchstone of ethical 
research.124  However, acquiring consent is much more involved than getting 
 
 119.  See 21 C.F.R § 11.1 (2016). 
 120.  See 21 C.F.R § 11.2 (2016). 
 121.  See Breaches Affecting 500 or More Individuals, U.S. DEP’T OF HEALTH & HUMAN 
SERV. OFFICE OF CIVIL RIGHTS,  https://ocrportal.hhs.gov/ocr/breach/breach_report.jsf;jsessionid 
=8E03A0B57574BDB35FF1AEFE5DE51A95 (last visited Mar. 29, 2017). 
 122.  See id. 
 123.  See Jason Karn, The Top 10 HIPAA Violations and How to Prevent Them, NUEMD (June 
16, 2015), http://www.nuemd.com/blog/top-10-hipaa-violations-prevent-them. 
 124.  See History of Research Ethics, UNIV. OF MISSOURI-KANSAS CITY, http://ors.umkc.edu 
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a signature on a consent form.125  Obtaining informed consent requires “full 
disclosure of the nature of the research and the participant’s involvement; 
adequate comprehension on the part of the potential participant; and the 
participants voluntary choice to participate.”126  Accordingly, obtaining 
informed consent should be viewed as a bi-directional and ongoing 
communication process, not a one-time meeting and one-way disclosure 
resulting in a signed piece of paper.127 
Prospective participants of a clinical trial must be fully informed about 
the potential risks and rewards of participating in the clinical trial, and be 
given “sufficient opportunity to consider whether or not to participate” in the 
study.128  Unfortunately, explaining the intricacies of a clinical trial may 
become exponentially more difficult as medicine continues to advance.  For 
example, even the best of clinicians could have a hard time explaining to a 
patient with no medical background or knowledge how a new, cutting edge 
medicine is interacting with the body.129 
Additionally, participants in the clinical trial process must be given the 
opportunity to ask questions about the treatment, and should be encouraged 
to seek clarification if they do not comprehend something relevant to the 
clinical trial.130  Unfortunately, providing participants with the opportunity 
to ask questions can be stifled by two factors.  First, some patients may not 
know what to ask; depending on the complexity of the treatment; individuals 
may lack the requisite comprehension of the material to ask relevant 
questions.  Second, individuals may be too intimidated or embarrassed to ask 
 
/research-compliance-(iacuc-ibc-irb-rsc)/institutional-review-board-(irb)/history-of-research-ethics 
(last visited Mar. 29, 2017). 
 125.  See 21 C.F.R. § 50.20 (2017) (listing the requirements for informed consent); see also 
Informed Consent for Clinical Trials, http://www.fda.gov/ForPatients/ClinicalTrials/Informed 
Consent/default.htm (last visited Mar. 26, 2017). 
 126.  See Required Components of Informed Consent, CORNELL UNIV., https://www.irb.corn 
ell.edu/forms/consent.htm (last visited Mar. 29, 2017) (analyzing the requirements for fully 
informed consent); see also 21 C.F.R. § 50.25 (2011) (discussing the elements of informed consent 
specific to clinical trials). 
 127.  See Helen L. Stiffler, Guidelines for Obtaining Informed Consent for Clinical Research, 
APPLIED CLINICAL TRIALS ONLINE (Nov. 2, 2003), http://www.appliedclinicaltrialsonline.com/ 
guidelines-obtaining-informed-consent-clinical-research. 
 128.  See 21 C.F.R. § 50.20 (2017). 
 129.  See Jennifer Fong Ha and Nancy Longnecker, Doctor-Patient Communication: A Review, 
10 OCHSNER J., 38 (Spring 2010), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096184 
/#i1524-5012-10-1-38-DiMatteo1 (finding that “75% of orthopedic surgeons surveyed believed 
that they communicated satisfactorily with their patients, but only 21% of the patients reported 
satisfactory communication with their doctors.  Patient surveys have consistently shown that they 
want better communication with their doctors”). 
 130.  See Informed consent for clinical Trials, U.S. FOOD & DRUG ADMIN., http://www.fda. 
gov/ForPatients/ClinicalTrials/InformedConsent/default.htm (last updated Feb. 25, 2016). 
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the research team a question.131  While these barriers to informed consent seem 
like speculation, some studies suggest that nearly one out of every five 
prospective participants in a clinical trial had difficulty understanding the 
informed consent document, and “15% were not satisfied that their question has 
been answered during the consent process.”132 
As discussed above in connection with trial related document 
distribution — large scale, global clinical trials are increasing in number.133  
As participants and doctors begin clinical trials that cross the globe, 
increased confusion and lack of comprehension is likely to proliferate 
commensurate with an international focus which will also bring mounting 
language barriers.134 
Although informed consent seems like a minor part of the clinical trial 
process, it is undeniably a critical aspect of ethical trials and patient care.  
Unlike a traditional doctor patient relationship, the research team in a clinical 
trial has a primary goal of scientific and medical advancement, which can be 
at odds with the best interests of the patient.135  Thus, for the sake of patient 
protection, fully informed consent and comprehension of the clinical trial is 
paramount. 
i.  Informed Consent and the Impact of Technology 
As mentioned previously in this article, some pharmaceutical industry 
leaders have already begun to adopt electronic informed consent, or 
“eConsent” systems.136  Additionally, in March 2015, the FDA issued draft 
guidance on the use of electronic informed consent systems, which the FDA 
defined as “[using] electronic systems and processes that may employ 
multiple electronic media . . . to convey information related to the study and 
 
 131.  See Are You Too Embarrassed to Ask Your Doctor?, WEBMD (May 9, 2005), 
http://www.webmd.com/fitness-exercise/features/are-you-too-embarrassed-to-ask-your-doctor#1 
(noting that fear of asking a doctor an embarrassing question is a common phenomenon). 
 132.  See Beverly H. Lorell et al., Informed Consent in Clinical Research: Consensus 
Recommendations for Reform Identified by an Expert Interview Panel, SAGEPUB (July 15, 2015), 
http://ctj.sagepub.com/content/12/6/692.full.pdf+html. 
 133.  See supra, text accompanying note note 102. 
 134.  See Lokesh P. Nijhawan et al., Informed Consent: Issues and Challenges, 4 J. ADV.  
PHARM. TECH. RES. 134 (2013), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777303/ (citing 
language barriers as a challenge in obtaining informed consent). 
 135.  See Benjamin Mason Meier, International Protection of Persons Undergoing Medical 
Experimentation: Protecting the Right of Informed Consent, 20 BERKELEY J. INT’L L. 513, 516 
(2002) (noting that “informed consent levels the playing field, providing the subject with the tools 
necessary to make a decision contrary to the wishes of the physician.”). 
 136.  See Keet and Morrie, supra text accompanying note 62. 
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to obtain and document informed consent.”137  Although nothing in the draft 
guidance is legally binding authority, it sheds light on where the FDA 
unofficially stands in regards to eConsent adoption.138  In fact, the FDA’s 
draft guidance on the issue suggests that the FDA supports and will permit 
the use of electronic media in the informed consent process.139 
Throughout the draft guidance, and in the federal regulations governing 
consent, the FDA stresses the importance that patients understand the 
information that is being conveyed to them.140  This is where the industry 
can harness the positive potential of eConsent.  Instead of a piece of paper 
with writing on it, a complete eConsent package could be a downloadable 
file that a potential patient can review at their own pace in the comfort of 
their home or with their clinician, at the office or via video or telephone.141  
Instead of black and white text, the eConsent platform could include videos 
and interactive charts to keep the patient interested in the material.142  
Additionally, hyperlinks could be utilized to give simple definitions for 
complicated medical terminology.143 
Further, it is fully within the realm of technological possibility for real-
time chatting to occur between a patient and a medical professional.  Subjects 
could even submit questions anonymously to a centralized database, where 
they would be stored until an in-person meeting between a group of patients 
and medical professionals.  Doing so could help alleviate anxiety that may 
come with asking a question in person, and could even help address a 
common dilemma; patients not knowing what to ask - because of the belief 
that another patient will ask a question for them. 
For confirmation of patient consent review, there is currently 
technology in development that tracks the eyes of individuals as they read 
 
 137.  See Use of Electronic Informed Consent in Clinical Investigations, U.S. FOOD & DRUG 
ADMIN. (Dec. 2016), avaialable at http://www.fda.gov/downloads/drugs/guidancecomplianceregu 
latoryinformation/guidances/ucm436811.pdf. 
 138.  See id. at 5. 
 139.  See id.; see also Alexander Gaffney, FDA Says it’s OK With Modernizing the Clinical 
Trial Informed Consent Process, REGULATORY AFFAIRS PROF’L SOC’Y (Mar. 9, 2015), 
http://www.raps.org/Regulatory-Focus/News/2015/03/09/21673/FDA-Says-its-OK-With-Modern 
izing-the-Clinical-Trial-Informed-Consent-Process/. 
 140.  See U.S. FOOD & DRUG ADMIN., supra note 137. 
 141.  See Keet & Morrie, supra note 62 (noting the use of text, video, audio, podcasts and 
interactive web sites disseminate information about the study to patients). 
 142.  See The Definitive eConsent Solution, DRUGDEV, https://www.drugdev.com/solutions/ 
drugdev-econsent/ (last visited Mar. 29, 2017) (noting the use of “explanatory videos, audio 
narration, and glossary terms to put ‘informed’ back into informed patient consent”). 
 143.  See id. 
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on a tablet or computer screen.144  Some eye tracking technology “is capable 
of monitoring your eyes in order to define words if you stare at them puzzled, 
eliminating non-essential information when you’re skimming” and can even 
remind the reader of exactly where he or she previously stopped reading.145  
This showcases how eConsent systems can continue to utilize technological 
advances for the benefit of patients. 
Similarly, eConsent management systems can be used to limit the 
possibility of accidently sharing a patient’s health records with a party that 
the patient did not consent to viewing the records.146  Through the use of 
“structured data”, or data that a computer can understand and extract discrete 
elements of, eConsent management systems can control what sections of a 
patient’s health records may be disseminated to specific parties.147  For example, 
the eConsent system can bar one clinician from seeing drug abuse history of a 
patient, but could allow another clinician to see it if the patient consents.148  
Accordingly, this type of eConsent management system can “ensure[] the sender 
and receiver are authorized to engage in the exchange” while enforcing 
applicable federal, state, and local law.149 
III.  Policy 
Since President Obama’s passage of the American Recovery and 
Reinvestment Act (ARRA), the digitization of medicine has been on the 
forefront of the changing legal landscape.150  Although the ARRA was 
limited to the adoption of electronic health records in medicine, it set up the 
framework for technology to play a larger part in all stages of medicine, 
including clinical trials. 
 
 144.  See This is Eye Tracking, TOBII, http://www.tobii.com/group/about/this-is-eye-tracking/ 
(last visited Mar. 29, 2017). 
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 146.  See Electronic Consent Management: Landscape Assessment, Challenges, and 
Technology, MITRE (Oct. 29, 2014), available at https://www.healthit.gov/sites/default/files/priv 
acysecurity/ecm_finalreport_forrelease62415.pdf. 
 147.  See id. at 6. 
 148.  See id. 
 149.  See id. at 6 (reasoning that an eConsent system can “negotiate the entire transaction in an 
automated way that enforces the patient’s electronic consent directive”). 
 150.  See American Recovery and Reinvestment Act of 2009, Pub. L. No. 111-5, 123 Stat. 115 
(2009); see also Sharona Hoffman & Andy Podgurski, 24 BERKELEY TECH. L.J. 1523, 1525 (2009) 
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In September 2013, the FDA released draft guidance regarding the use 
of “electronic source data in FDA-regulated clinical investigations.”151  This 
shows that the FDA is ready and willing to move the clinical trial process 
into the digital age.  Although 21 CFR 11 is dedicated to controls for 
electronic records and electronic signatures, the references to closed and 
open systems show how dated these regulations are.152  Accordingly, 
although regulatory bodies have been willing to adopt electronic 
advancements in clinical trials, there is still work to be done. 
However, this does not mean that the FDA is fighting an electronic 
revolution in medicine.  To the contrary, they seem to be doing their best to 
embrace it.  In 2012, the Food and Drug Administration Safety and 
Innovation Act (FDASIA) suggested that future FDA submissions for New 
Drug Applications should only be accepted in electronic format.153  The 
FDASIA stated that this change should take place “no earlier than 24 months 
after the issuance of a final guidance issued” relating to the process for 
electronic submissions.154  This final guidance was published on May 5, 
2015,155 meaning that after May 5, 2017, most drug submissions will need to 
be submitted to the FDA via electronic submission.156  Thus, if the 
submissions need to be in electronic format, that suggests that the data and 
analytics of the associated clinical trials will be too. 
Further, in June 2015, the FDA published a notice in the Federal 
Register, seeking “demonstration projects to test the capability and evaluate 
performance of using an end-to-end Electronic Health Record (EHR)-to-
Electronic Data Capture (EDC) single-point data capture approach, using 
established data and implementation standards in a regulated clinical 
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research environment.”157  In response to this notice, the FDA received 41 
proposals from interested parties, seeking to “test standards-based 
technology solutions for collection of related healthcare and clinical research 
information.”158  This shows two important developments in the growth of 
technology and healthcare.  First, the FDA is interested in embracing the 
digital clinical trial process and they want to do so with the guidance of the 
industry.159  Second, industry leaders are ready and willing to assist the FDA 
in establishing workable standards for adopting electronic processes in the 
clinical trial field. 
Moreover, the technological advancements available to facilitate the 
drug development process are beneficial to all parties involved.  As discussed 
at length above, increasing the use of technology saves time and money for 
the sponsors and CROs during the developmental stage.160  Additionally, 
technology can help the FDA and other regulatory bodies speed up their 
approval process, by consolidating data into more manageable electronic 
formats.161  But most importantly, technological advances in clinical trials 
have the potential to impact patients by speeding up the time it takes new 
drugs to go from lab to market.162  The FDA already has guidelines for 
expediting the approval of new drugs for serious or life threatening 
diseases.163  But the hope for the future is that this “fast-track” would be 
unnecessary, because technology would allow all drugs to make it through 
the clinical trial process faster and safer.164 
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There is no doubt that technology is changing the healthcare industry.165  
The governing bodies charged with overseeing medicine and healthcare 
seem to be embracing the change, albeit rather slowly.  However, slow 
change is better than no change, and as technological advancements continue 
to change the way humans address healthcare, those same changes can be 
adopted to speed up the process of clinical trials and drug development.  
Although there may be instances where parties risk exposure to greater 
liability by embracing technology — that is a risk that the industry as a whole 
should accept.  The end goal of pharmaceuticals is to produce new treatments 
and cures for diseases, and any perceived, slight increased risk, if any, for 
achieving that end should not be a bar to the accelerated adoption of 
technology. 
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